2 results
Approved WMOCompleted
Primary:• To evaluate the ability of relugolix to achieve and maintain serum testosterone suppression to castrate levels (<= 50 ng/dL [1.7 nmol/L]) in men with androgen-sensitive advanced prostate cancer.Secondary:• To evaluate the time…
Approved WMORecruiting
Primary Objective There are two co-primary objectives; one regarding each tibial component configuration, fixed bearing (FB) and rotating platform (RP): 1) Evaluate change from preoperative baseline to the 2 yr timepoint in patient reported…